Table 3.
Rate of FEV1 Decline (ml/yr) Study Results
| Study | Length (yr) | n | Mean FEV1 (%) | Mean Age | Active | Placebo | Difference (95% CI) | Estimated Effective SD | Implied n/Group for 90% Power to Detect (2) |
|
|---|---|---|---|---|---|---|---|---|---|---|
| 12 ml/yr Difference | 15 ml/yr Difference | |||||||||
| SUMMIT (138) | 1–4* | 16,485 | 60 | 65 | 38 | 46 | −8 (−15, −1) | 154 | 3,462 | 2,216 |
| Zhou and colleagues (15) | 2 | 841 | 78 | 64 | 29 | 51 | −22 (−37, −6) | 110 | 1,766 | 1,131 |
| Copenhagen CHS (166) | 3 | 290 | 86 | 59 | 45 | 42 | 3 (−13, 19) | 69 | 695 | 445 |
| EUROSCOPE (167) | 3 | 1,277 | 77 | 52 | 57 | 69 | −12 NS | UNK | NS | NS |
| TORCH (168) | 3 | 6,112 | 44 | 65 | 42/43/39 | 55 | −16 (−25, −8) | 113 | 1,864 | 1,193 |
| BRONCUS (169) | 3 | 523 | 57 | 62 | 56 | 47 | 8 (−10, 25) | 97 | 1,374 | 879 |
| ISOLDE (170) | 3 | 751 | 50 | 64 | 50 | 59 | −9 (−3, 20) | 76 | 843 | 540 |
| Lung Health Study II (171) | 3.5–4.5* | 1,116 | 68 | 56 | 44 | 47 | −3 (−11, 5) | 70 | 716 | 458 |
| UPLIFT (40, 172) | 4 | 5,993 | 48 | 65 | 40 | 42 | −2 (−6, 2) | 72 | 757 | 485 |
| Lung Health Study I (68) | 5 | 5,887 | 78 | 48 | 30 | 66 | −31 UNK | 57 | 475 | 304 |
Definition of abbreviations: BRONCUS = Bronchitis Randomized on NAC Cost-Utility Study; CI = confidence interval; COPD = chronic obstructive pulmonary disease; Copenhagen CHS = Copenhagen City Heart Study; EUROSCOPE = European Respiratory Society Study on Chronic Obstructive Pulmonary Disease; ISOLDE = Inhaled Steroids in Obstructive Lung Disease in Europe; NS = not stated; SUMMIT = Study to Understand Mortality and Morbidity in COPD; TORCH = Towards a Revolution in COPD Health; UNK = unknown; UPLIFT = Understanding Potential Long-Term Impact on Function with Tiotropium.
*
Variable length follow up.